NeuroPace, Inc. (NPCE) News
Follow NeuroPace, Inc. (NPCE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 12 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
NPCE reports 21% revenue growth; FDA IGE approval could lift market
NPCE said it delivered 21% revenue growth and a robust patient pipeline. It cited FDA approval for IGE that could expand the addressable market by 20%, alongside AI-driven tools and remote monitoring.
REGULATION | Sep 09, 2026, 04:11 PM UTC
M
NPCE management cites FDA approval potential for IGE expansion
NPCE management is optimistic about FDA approval for IGE, saying it could expand the addressable market by 20%. It also cites 21% core business growth and investments in sales, marketing and digital tools.
REGULATION | Sep 09, 2026, 03:51 PM UTC
L
NPCE IGE FDA approval could enable growth, commercialization by 2027
Drug-resistant epilepsy is cited as under-penetrated. Initiatives and expanded indications like IGE are expected to drive adoption, with potential FDA approval for IGE in 2027 and a subsequent commercialization ramp.
REGULATION | Sep 08, 2026, 01:46 PM UTC
L
NPCE highlights RNS system clinical strength and FDA engagement
NPCE says drug-resistant epilepsy remains under-penetrated and points to Project CARE and expanded IGE indications to drive adoption. It also cites strong RNS clinical results and ongoing FDA engagement targeting a poten
REGULATION | Sep 08, 2026, 01:08 PM UTC
L
NeuroPace management to participate in 2026 Cantor healthcare conference
NeuroPace said its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference, including a fireside chat.
EQUITY | Sep 01, 2026, 09:02 PM UTC
L
NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est
NeuroPace (NASDAQ: NPCE ) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.
EARNINGS | Aug 11, 2026, 08:08 PM UTC
L
NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate
NeuroPace (NASDAQ: NPCE ) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same
EARNINGS | Aug 11, 2026, 08:07 PM UTC
L
NPCE -7% premarket after FDA headlines
NPCE -7% premarket after FDA headlines
REGULATION | Jul 29, 2026, 12:47 PM UTC
H
Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Sess
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Avis Budget Group Inc (NASDAQ: CAR ) fell sharply in pre-market trading after the company reported worse-than-e
EARNINGS | Jul 29, 2026, 12:03 PM UTC
L
NPCE Neuropace receives FDA guidance on pma supplement for indication expansion into idiopathic generalized epilepsy
NPCE Neuropace receives FDA guidance on pma supplement for indication expansion into idiopathic generalized epilepsy
EARNINGS | Jul 28, 2026, 08:01 PM UTC
L
NPCE Initiated Outperform W/$22.00 PT at Mizuho
NPCE Initiated Outperform W/$22.00 PT at Mizuho
EQUITY | Jul 23, 2026, 11:55 AM UTC
L
NPCE new Outperform W/ $22 PT @ Mizuho
NPCE new Outperform W/ $22 PT @ Mizuho
EQUITY | Jul 23, 2026, 11:38 AM UTC